Regencell Bioscience Holdings LtdRGC
Price (close)
$6.17
Market cap
$3.1B
P/E
—
Revenue (FY)
—
Net income
-$3.6M
Dividend yield
—
1-year total return
-59.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Regencell Bioscience Holdings Ltd does.
goal is to save and improve the lives of ADHD patients, ASD patients, their families and caregivers and become a market leader for the
best natural and holistic treatment globally. The TCM Practitioner has been treating ADHD and ASD patients for over 30 years and
we intend to commercialize the TCM formula utilized in his treatment first in Hong Kong and subsequently globalize the use of such TCM
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$812,371 | -$1.3M | -$7.4M | -$5.9M | -$4.3M | -$3.6M |
| Free cash flow | -$844,410 | — | -$6.0M | -$5.0M | -$4.0M | -$3.3M |
More on RGC.
- Regencell Bioscience Holdings Ltd summary
- Regencell Bioscience Holdings Ltd financial statements
- Regencell Bioscience Holdings Ltd key metrics
- Regencell Bioscience Holdings Ltd health scores and style box
- Regencell Bioscience Holdings Ltd earnings
- Regencell Bioscience Holdings Ltd dividends
- Regencell Bioscience Holdings Ltd valuation
- Regencell Bioscience Holdings Ltd ownership and insiders
- Regencell Bioscience Holdings Ltd peers
Figures from Regencell Bioscience Holdings Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.